Form 10-K Valeant Pharmaceuticals For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Valeant's (VRX) Debt Covenants Remain a Concern After 10K Filing - Piper Jaffray
May 2, 2016 7:43 AM EDTPiper Jaffray analyst, David Amsellem, noted that Valeant's (NYSE: VRX) 10K for 2015 contained one kernel of good news: it cured the default on its senior notes related to the late filing. Unfortunately that was "the only piece of good news". Here are the problems:
Wholesaler inventory... More
BMO Capital 'Incrementally Positive' on Valeant (VRX) 10K, But Notes Important Changes in Fundamentals
April 29, 2016 11:23 AM EDTBMO Capital analyst Alex Arfaei weighed in Valeant Pharmaceuticals (NYSE: VRX) after the 10K. He said it was incrementally positive, although notes important change in fundamentals.
Arfaei commented, "Valeant is now in compliance of its debt agreements, and should avert technical default on its debt. As far as we can tell, the new restatement is related to 4Q15, and it is modest. 4Q15 revenue is now $21MM lower because of Addyi and Xifaxan adjustments, this brings non-GAAP EPS down from $2.50 to $2.40 under the... More
Valeant Pharma (VRX) Announces Filing of 10-K for FY15
April 29, 2016 7:29 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that it has filed with the U.S. Securities and Exchange Commission (the "SEC") its Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the "Form 10-K"). This Form 10-K includes consolidated financial statements for the years ended December 31, 2013, 2014 and 2015. The audited consolidated financial statements for the year ended December 31, 2014 are restated. The Company has also restated certain unaudited quarterly results related to the three months ended December 31, 2014, the three months... More
